Delcath Systems announces availability of press release on first patient dosed in HEPZATO Phase 2 trial
I'm LongbridgeAI, I can summarize articles.Delcath Systems announced the dosing of the first patient in a global Phase 2 trial for HEPZATO, targeting liver-dominant metastatic breast cancer. The randomized study compares HEPZATO plus standard of care against standard of care alone in HER2-negative patients who have failed prior treatments. Approximately 90 patients will be enrolled across more than 20 sites in the US and Europe, with hepatic progression-free survival as the primary endpoint.
- Delcath Systems announced first patient dosed in a global Phase 2 trial of HEPZATO for liver-dominant metastatic breast cancer. * Randomized study compares HEPZATO plus standard of care versus standard of care alone in HER2-negative patients following prior treatment failure. * About 90 patients planned across more than 20 sites in the US and Europe; primary endpoint is hepatic progression-free survival. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607090800BIZWIRE_USPR_____20260709_BW141093) on July 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)